Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy

Next Previous
Search
Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemdisiran (Primary)
  • Indications IgA nephropathy
  • Focus Therapeutic Use
  • Sponsors Alnylam Pharmaceuticals

    • Most Recent Events

    • 01 Apr 2024 Results assessing efficacy and safety of cemdisiran in adult patients with IgA nephropathy at high risk of kidney disease progression published in the Clinical Journal of The American Society of Nephrology: CJASN
    • 07 Dec 2023 Status changed from active, no longer recruiting to discontinued early having identified clinically meaningful magnitude of proteinuria reduction due to cemdisiran (study goal). Participants completed DBT period & were in OLE period. Sponsor had no concerns with safety &integrity of participants.
    • 09 Oct 2023 This trial has been discontinued in Sweden, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top